Among the most consolidated therapies for DKD is the use of ace inhibitors that are a blocker of the enzyme of conversion of angiotensin I in angiotensin II, representing a cornerstone blocking the renin angiotensin aldosterone system and limiting the previously seen damage cascade. This evidence concerns the gene REN and diabetic kidney disease.